Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 69.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,277 shares of the biotechnology company’s stock after acquiring an additional 1,756 shares during the quarter. SG Americas Securities LLC’s holdings in Blueprint Medicines were worth $373,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Empirical Asset Management LLC acquired a new stake in Blueprint Medicines in the fourth quarter valued at $2,348,000. Exome Asset Management LLC purchased a new stake in shares of Blueprint Medicines during the 3rd quarter worth about $3,395,000. Franklin Resources Inc. grew its holdings in shares of Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after purchasing an additional 265 shares during the period. Synovus Financial Corp grew its holdings in shares of Blueprint Medicines by 4.0% during the 3rd quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock worth $2,224,000 after purchasing an additional 922 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Blueprint Medicines during the 3rd quarter worth approximately $202,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Wells Fargo & Company cut their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Wednesday, January 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Monday, January 13th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $123.56.

Insider Buying and Selling at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now owns 71,657 shares of the company’s stock, valued at approximately $6,814,580.70. This represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock valued at $4,984,696 in the last 90 days. 4.21% of the stock is currently owned by company insiders.

Blueprint Medicines Price Performance

Blueprint Medicines stock opened at $111.50 on Tuesday. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The business’s 50 day simple moving average is $98.13 and its 200 day simple moving average is $95.03. The company has a market cap of $7.08 billion, a price-to-earnings ratio of -52.84 and a beta of 0.61.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.